Key Insights

Highlights

Success Rate

80% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

11.4%

4 terminated out of 35 trials

Success Rate

80.0%

-6.5% vs benchmark

Late-Stage Pipeline

40%

14 trials in Phase 3/4

Results Transparency

38%

6 of 16 completed with results

Key Signals

6 with results80% success

Data Visualizations

Phase Distribution

29Total
Not Applicable (8)
Early P 1 (1)
P 1 (2)
P 2 (4)
P 3 (3)
P 4 (11)

Trial Status

Completed16
Unknown7
Recruiting6
Terminated4
Withdrawn1
Not Yet Recruiting1

Trial Success Rate

80.0%

Benchmark: 86.5%

Based on 16 completed trials

Clinical Trials (35)

Showing 20 of 20 trials
NCT05938712Phase 2RecruitingPrimary

The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

NCT02555566Not ApplicableCompletedPrimary

Role of Epoxyeicosatrienoic Acids in Chronic Allograft Nephropathy - The TRANSPLANT-EETs Study

NCT05077254Phase 2CompletedPrimary

COVID Protection After Transplant-Immunosuppression Reduction

NCT07532694Not ApplicableRecruiting

Diode Laser-Assisted Periodontal Therapy in Kidney Transplant Recipients

NCT05702398Early Phase 1Recruiting

Pilot Trial of Supplemental Vitamin A and Nicotinamide

NCT06751992Phase 4RecruitingPrimary

Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients

NCT07370727Not ApplicableRecruitingPrimary

Velocity-Based Resistance Training in Kidney Transplant Recipients

NCT01150487Not ApplicableCompleted

Paired Marrow Aspirations to Assess Assays in Sensitized Renal Allograft Recipients

NCT03979365Phase 4CompletedPrimary

Envarsus XR Compared to Immediate Release Tacrolimus

NCT06881927Phase 4Not Yet Recruiting

Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure

NCT04757883TerminatedPrimary

Immunological Follow-up After SARS CoV2 Vaccination in Kidney Transplant Recipients

NCT04969263Phase 2CompletedPrimary

COVID-19 Protection After Transplant Pilot Study

NCT04965935Phase 3CompletedPrimary

Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients

NCT05425498Not ApplicableCompletedPrimary

The Effects of Physical Activity Behavior Change in Kidney Transplant Recipients

NCT06806670Not ApplicableRecruitingPrimary

Exercise and Diet Effects in Reducing Cardiovascular Risk in Kidney Transplant Recipients

NCT02268201Phase 4TerminatedPrimary

A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule

NCT02392312CompletedPrimary

Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients

NCT04066114Phase 1Completed

Treg Modulation With CD28 and IL-6 Receptor Antagonists

NCT04444843Phase 4UnknownPrimary

Risk Factors of Chinese Kidney Transplant Recipients DSA Based on MPA Immunosuppressive Regimen

NCT05293704Phase 4UnknownPrimary

An Open Study on the Preventive Effect of Early Mizoribine Conversion on BKV Nephropathy in Renal Transplant Recipients

Scroll to load more

Research Network

Activity Timeline